Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. J of Skin [Internet]. 2021 Nov. 5 [cited 2025 May 18];5(6):s39. Available from: https://skin.dermsquared.com/skin/article/view/1390